Action AXSM AXSOME THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Axsome Therapeutics, Inc.

Actions

AXSM

US05464T1043

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 11/06/2024 		Varia. 5j. Varia. 1 janv.
71,07 USD -1,02 % Graphique intraday de Axsome Therapeutics, Inc. -1,62 % -10,70 %
05/06 AXSOME THERAPEUTICS, INC. : RBC Capital Markets persiste à l'achat ZM
05/06 Axsome Therapeutics déclare avoir réglé le litige sur le brevet Sunosi avec Unichem Laboratories MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Axsome therapeutics settles sunosi patent litigation with unichem laboratories
Axsome Therapeutics Says It Settled Sunosi Patent Litigation With Unichem Laboratories
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics Q1 Loss Widens, Revenue Declines -- Shares Advance Pre-Bell
Axsome: Q1 Earnings Snapshot
Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q1 Revenue $75M, vs. Street Est of $72.9M
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
North American Morning Briefing : More Earnings -2-
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action AXSM
  4. Actualités Axsome Therapeutics, Inc.
  5. Autres langues